GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00027642 | Stomach | CSG | immune response-regulating signaling pathway | 43/1034 | 468/18723 | 7.58e-04 | 1.04e-02 | 43 |
GO:006102821 | Stomach | CSG | establishment of endothelial barrier | 9/1034 | 46/18723 | 7.99e-04 | 1.09e-02 | 9 |
GO:00603262 | Stomach | CSG | cell chemotaxis | 31/1034 | 310/18723 | 1.04e-03 | 1.33e-02 | 31 |
GO:00313412 | Stomach | CSG | regulation of cell killing | 14/1034 | 99/18723 | 1.06e-03 | 1.34e-02 | 14 |
GO:200037721 | Stomach | CSG | regulation of reactive oxygen species metabolic process | 19/1034 | 157/18723 | 1.08e-03 | 1.35e-02 | 19 |
GO:00026882 | Stomach | CSG | regulation of leukocyte chemotaxis | 16/1034 | 122/18723 | 1.11e-03 | 1.37e-02 | 16 |
GO:007169221 | Stomach | CSG | protein localization to extracellular region | 35/1034 | 368/18723 | 1.25e-03 | 1.50e-02 | 35 |
GO:00018192 | Stomach | CSG | positive regulation of cytokine production | 42/1034 | 467/18723 | 1.32e-03 | 1.56e-02 | 42 |
GO:000315821 | Stomach | CSG | endothelium development | 17/1034 | 136/18723 | 1.35e-03 | 1.57e-02 | 17 |
GO:005122221 | Stomach | CSG | positive regulation of protein transport | 30/1034 | 303/18723 | 1.46e-03 | 1.68e-02 | 30 |
GO:005071421 | Stomach | CSG | positive regulation of protein secretion | 17/1034 | 137/18723 | 1.46e-03 | 1.68e-02 | 17 |
GO:000930621 | Stomach | CSG | protein secretion | 34/1034 | 359/18723 | 1.57e-03 | 1.75e-02 | 34 |
GO:003559221 | Stomach | CSG | establishment of protein localization to extracellular region | 34/1034 | 360/18723 | 1.64e-03 | 1.81e-02 | 34 |
GO:005070821 | Stomach | CSG | regulation of protein secretion | 27/1034 | 268/18723 | 1.92e-03 | 2.02e-02 | 27 |
GO:00030942 | Stomach | CSG | glomerular filtration | 6/1034 | 25/18723 | 2.00e-03 | 2.08e-02 | 6 |
GO:005087821 | Stomach | CSG | regulation of body fluid levels | 35/1034 | 379/18723 | 2.07e-03 | 2.14e-02 | 35 |
GO:19004262 | Stomach | CSG | positive regulation of defense response to bacterium | 4/1034 | 11/18723 | 2.23e-03 | 2.25e-02 | 4 |
GO:19004242 | Stomach | CSG | regulation of defense response to bacterium | 5/1034 | 18/18723 | 2.38e-03 | 2.38e-02 | 5 |
GO:00972052 | Stomach | CSG | renal filtration | 6/1034 | 26/18723 | 2.48e-03 | 2.45e-02 | 6 |
GO:00103242 | Stomach | CSG | membrane invagination | 17/1034 | 144/18723 | 2.51e-03 | 2.46e-02 | 17 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513022 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0513032 | Liver | Cirrhotic | Pathogenic Escherichia coli infection | 88/2530 | 197/8465 | 6.48e-06 | 6.24e-05 | 3.84e-05 | 88 |
hsa0513042 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0513052 | Liver | HCC | Pathogenic Escherichia coli infection | 129/4020 | 197/8465 | 2.02e-07 | 2.50e-06 | 1.39e-06 | 129 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481051 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2R | SNV | Missense_Mutation | | c.978N>G | p.Phe326Leu | p.F326L | P25116 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
F2R | SNV | Missense_Mutation | | c.253N>A | p.Pro85Thr | p.P85T | P25116 | protein_coding | tolerated(0.39) | benign(0.005) | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
F2R | SNV | Missense_Mutation | novel | c.1106N>C | p.Leu369Pro | p.L369P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AO-A0JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
F2R | SNV | Missense_Mutation | | c.250N>T | p.Leu84Phe | p.L84F | P25116 | protein_coding | tolerated(0.69) | benign(0.063) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
F2R | SNV | Missense_Mutation | | c.238N>G | p.Leu80Val | p.L80V | P25116 | protein_coding | tolerated(0.55) | benign(0.039) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
F2R | insertion | Frame_Shift_Ins | novel | c.391_392insACACTACCAGGCTCTGCTCTGCTGTCTCTGAGTTGGTACTACTC | p.Met131AsnfsTer16 | p.M131Nfs*16 | P25116 | protein_coding | | | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
F2R | SNV | Missense_Mutation | | c.299N>C | p.Trp100Ser | p.W100S | P25116 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
F2R | SNV | Missense_Mutation | novel | c.727N>C | p.Thr243Pro | p.T243P | P25116 | protein_coding | deleterious(0) | probably_damaging(0.936) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P25116 | protein_coding | tolerated(0.57) | benign(0.096) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
F2R | SNV | Missense_Mutation | | c.1210N>G | p.Met404Val | p.M404V | P25116 | protein_coding | tolerated(0.19) | benign(0) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | inhibitor | CHEMBL2013119 | RIGOSERTIB SODIUM | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | TYROSINE KINASE INHIBITOR | | 15383630 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | MORPHINE | MORPHINE | 12373743 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | ETHANOL | ALCOHOL | 16930224 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 405560412 | | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2103856 | ATOPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | CHEMBL2107386 | VORAPAXAR SULFATE | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | | WORTMANNIN | WORTMANNIN | 10318860,7559410,8955143 |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | antagonist | 178100871 | VORAPAXAR | |
2149 | F2R | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, CELL SURFACE | agonist | 178100667 | | |